| Literature DB >> 34428843 |
Izaura Helena Chaves de Meneses1, Gêisa Aiane de Morais Sampaio2, Rayssa Amaral Vieira3, Márcio José da Silva Campos3, Polliana Muniz Alves4, Matheus Melo Pithon5, Rogério Lacerda-Santos6.
Abstract
OBJECTIVE: The focus of this study was to evaluate the biocompatibility of ionomer cements modified with ethanolic extracts of propolis (EEP) in different concentrations and time intervals.Entities:
Year: 2021 PMID: 34428843 PMCID: PMC8890933 DOI: 10.1055/s-0041-1731888
Source DB: PubMed Journal: Eur J Dent
Fig. 1Flow diagram of animals used, groups, and tests evaluated.
Specificity, clone, manufacturer, dilution, antigen retrieval, and incubation time of the primary antibody used in the study
| Specificity | Clone | Manufacturer | Dilution | Antigen retrieval | Incubation | |
|---|---|---|---|---|---|---|
| CD68 | ED1 | Abcam | 1:1,500 | Citrato, pH 6, 95 degrees, 30 min | 60 min | |
Mean of scoresa attributed to the cements, after time interval difference
| Condition | Groups |
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | M10 | M25 | M50 | KC | KC10 | KC25 | KC50 |
| |||
| a
For each sample of the study, five representative sections of the histological condition of the tissue were analyzed, when all five sections of the tissue showed the same histological condition. Scores: 1, absent (5.00); 2, scarce (10.00); 3, moderate (15.00); and 4, intense (20.00).
| |||||||||||
| Inflammatory infiltrate | |||||||||||
| 7 | 13.75 AB | 20.00 A | 18.75 AB | 16.25 AB | 15.00 AB | 20.00 A | 18.75 AB | 15.00 AB | 10.00 B | 0.01 | |
| 15 | 11.25 AB | 16.25 A | 13.75 AB | 11.25 AB | 12.50 AB | 16.25 A | 13.75 AB | 10.00 AB | 7.50 B | 0.01 | |
| 30 | 10.00 AB | 12.50 AB | 12.50 AB | 10.00 AB | 10.00 AB | 13.75 A | 11.25 AB | 10.00 AB | 6.25 B | 0.01 | |
| Collagen | |||||||||||
| 7 | 12.50 AB | 8.75 A | 10.00 AB | 11.25 AB | 11.25 AB | 8.75 A | 10.00 AB | 11.25 AB | 15.00 B | 0.01 | |
| 15 | 16.25 AB | 10.00 A | 16.25 AB | 17.50 AB | 16.25 AB | 15.00 AB | 17.50 AB | 18.75 B | 18.75 B | 0.04 | |
| 30 | 18.75 | 16.25 | 17.50 | 18.75 | 20.00 | 18.75 | 20.00 | 20.00 | 20.00 | 0.14 | |
Fig. 2Immunomarking for antibody CD68. In time interval of 7 days: ( A ) In Group M10, intense immunomarking of CD68 was noted, with brownish cytoplasm immunopositive for multinucleated giant cells (MGCs) and macrophages (MOs) close to the exogenous material (EM) enveloped by MGCs (IH, 400X magnification; scale: 25 µm). ( B ) In Group M50, moderate immunomarking of CD68 was observed for MGCs and MOs (IH, 400X magnification; scale: 25 µm). ( C ) In Group KC10, intense immunomarking of CD68 was observed, with brownish cytoplasm immunopositive for MGCs and MOs throughout the cavity with polyethylene tube implant (PT) (IH, 400X magnification; scale: 25 µm). ( D ) In Group KC50, moderate immunomarking of CD68 was observed for MGCs and MOs (IH, 400X magnification; scale: 25 µm). ( E ) In Group Control, absence of immunoreactivity to CD68 was observed for MGCs and MOs around the cavity with PT (IH, 100X magnification; scale: 100 µm). In time interval of 15 days: ( F ) In Group M10, intense immunomarking of CD68 was noted, with brownish cytoplasm immunopositive for MGCs and MOs with immunopositive brownish cytoplasm close to the EM and around the cavity with PT (IH, 400X magnification; scale: 25 µm). ( G ) In Group M50, low immunomarking of CD68 was observed for MGCs and MOs (IH, 400X magnification; scale: 25 µm). ( H ) In Group KC10, intense immunomarking of CD68 was observed for MGCs and MOs with immunopositive brownish cytoplasm close to EM (IH, 400X magnification; scale: 25 µm). ( I ) In Group KC50, low immunomarking of CD68 was observed for MGCs and MOs surrounding cavity with PT (IH, 400X magnification; scale: 25 µm). ( J ) In Group Control, absence of immunoreactivity to CD68 was observed for MGCs and MOs surrounding cavity with PT (IH, 200X magnification; scale: 50 µm). In time interval of 30 days : ( K ) In Group M10, moderate immunomarking of CD68 was noted, with brownish cytoplasm immunopositive for MGCs and MOs in the internal region of the cavity with PT (IH, 400X magnification; scale: 25 µm). ( L ) In Group M50, scarce immunomarking of CD68 was observed for MGCs and MOs surrounding cavity with PT (200X magnification; scale: 50 µm). ( M ) In Group KC10, moderate immunomarking of CD68 was observed, with brownish cytoplasm immunopositive for MOs and low quantity of MGCs surrounding the cavity (IH, 400X magnification; scale: 25 µm). ( N ) In Group KC50, scarce immunomarking of CD68 was observed for MGCs and MOs surrounding cavity with PT (IH, 200X magnification; scale: 50 µm). ( O ) In Group Control, absence of immunoreactivity to CD68 was observed for MGCs and MOs surrounding the cavity with PT (IH, 400X magnification; scale: 25 µm).
Immunohistochemical analysis of the quantity of multinucleated giant cells and macrophages, after the time intervals of 7, 15, and 30 d
| Condition time/Days | Groups | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | M10 | M25 | M50 | KC | KC10 | KC25 | KC50 | C |
| ||
|
Note: These values represent the mean quantity of cells found in the histological sections representative of the tissue evaluated (
| |||||||||||
| Multinucleated giant cells | |||||||||||
| 7 | 1.00 AB | 5.00 A | 2.00 AB | 1.00 AB | 1.00 AB | 4.00 A | 2.00 AB | 1.00 AB | 0.00 B | 0.01 | |
| 15 | 0.00 A | 3.00 B | 1.00 AB | 1.00 AB | 0.00 A | 3.00 B | 1.00 AB | 0.00 A | 0.00 A | 0.01 | |
| 30 | 0.00 A | 2.00 B | 0.00 A | 0.00 A | 0.00 A | 1.00 AB | 1.00 AB | 0.00 A | 0.00 A | 0.01 | |
| Macrophages | |||||||||||
| 7 | 46.40 A | 91.62 B | 71.90 AB | 54.67 AB | 61.05 AB | 83.35 B | 67.90 AB | 54.35 AB | 22.21 A | 0.01 | |
| 15 | 55.35 AB | 98.57 A | 77.92 AB | 50.42 B | 69.10 AB | 97.95 A | 74.72 AB | 59.70 AB | 14.82 B | 0.01 | |
| 30 | 42.17 A | 67.92 B | 61.05 AB | 47.07 AB | 52.30 AB | 72.20 B | 63.00 AB | 57.12 AB | 11.45 A | 0.01 | |